Exact Mass: 644.3924

Exact Mass Matches: 644.3924

Found 341 metabolites which its exact mass value is equals to given mass value 644.3924, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

O-Methylganoderic acid O

(2E)-5-(acetyloxy)-6-[5,12-bis(acetyloxy)-9-methoxy-2,6,6,11,15-pentamethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-1(10)-en-14-yl]-2-methylhept-2-enoic acid

C37H56O9 (644.3924)


O-Methylganoderic acid O is found in mushrooms. O-Methylganoderic acid O is a constituent of cultured mycelium of Ganoderma lucidum (reishi) Constituent of cultured mycelium of Ganoderma lucidum (reishi). O-Methylganoderic acid O is found in mushrooms.

   

PA(14:0/18:2(9Z,12Z))

[(2R)-2-[(9Z,12Z)-octadeca-9,12-dienoyloxy]-3-(tetradecanoyloxy)propoxy]phosphonic acid

C35H65O8P (644.4417)


PA(14:0/18:2(9Z,12Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(14:0/18:2(9Z,12Z)), in particular, consists of one chain of myristic acid at the C-1 position and one chain of linoleic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

   

PA(18:1(11Z)/14:1(9Z))

[(2R)-3-[(11Z)-octadec-11-enoyloxy]-2-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C35H65O8P (644.4417)


PA(18:1(11Z)/14:1(9Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(18:1(11Z)/14:1(9Z)), in particular, consists of one chain of cis-vaccenic acid at the C-1 position and one chain of myristoleic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

   

PA(18:1(9Z)/14:1(9Z))

[(2R)-3-[(9Z)-octadec-9-enoyloxy]-2-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C35H65O8P (644.4417)


PA(18:1(9Z)/14:1(9Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(18:1(9Z)/14:1(9Z)), in particular, consists of one chain of oleic acid at the C-1 position and one chain of myristoleic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

   

PA(18:2(9Z,12Z)/14:0)

[(2R)-3-[(9Z,12Z)-octadeca-9,12-dienoyloxy]-2-(tetradecanoyloxy)propoxy]phosphonic acid

C35H65O8P (644.4417)


PA(18:2(9Z,12Z)/14:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(18:2(9Z,12Z)/14:0), in particular, consists of one chain of linoleic acid at the C-1 position and one chain of myristic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

   

2,2'-{Oxybis[(2,1-phenylene)oxy]}bis(N,N-dicyclohexylacetamide)

N,N-dicyclohexyl-2-(2-{2-[(dicyclohexylcarbamoyl)methoxy]phenoxy}phenoxy)acetamide

C40H56N2O5 (644.4189)


   

PA(10:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R))

[(2R)-3-(decanoyloxy)-2-{[(5R,6Z,8E,10E,12S,14Z)-5,12-dihydroxyicosa-6,8,10,14-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O10P (644.3689)


PA(10:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of Leukotriene B4 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/10:0)

[(2R)-2-(decanoyloxy)-3-{[(5S,6Z,8E,10E,12R,14Z)-5,12-dihydroxyicosa-6,8,10,14-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O10P (644.3689)


PA(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/10:0), in particular, consists of one chain of one Leukotriene B4 at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(10:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S))

[(2R)-3-(decanoyloxy)-2-{[(5S,6E,8Z,11Z,13E,15R)-5,15-dihydroxyicosa-6,8,11,13-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O10P (644.3689)


PA(10:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 5(S),15(S)-Dihydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/10:0)

[(2R)-2-(decanoyloxy)-3-{[(5R,6E,8Z,11Z,13E,15S)-5,15-dihydroxyicosa-6,8,11,13-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O10P (644.3689)


PA(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/10:0), in particular, consists of one chain of one 5(S),15(S)-Dihydroxyeicosatetraenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(10:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R))

[(2R)-3-(decanoyloxy)-2-{[(5R,6R,8Z,11Z,14Z,17Z)-5,6-dihydroxyicosa-8,11,14,17-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O10P (644.3689)


PA(10:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 5,6-Dihydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/10:0)

[(2R)-2-(decanoyloxy)-3-{[(5S,6S,8Z,11Z,14Z,17Z)-5,6-dihydroxyicosa-8,11,14,17-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O10P (644.3689)


PA(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/10:0), in particular, consists of one chain of one 5,6-Dihydroxyeicosatetraenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(13:0/18:2(10E,12Z)+=O(9))

[(2R)-2-{[(10E,12Z)-9-oxooctadeca-10,12-dienoyl]oxy}-3-(tridecanoyloxy)propoxy]phosphonic acid

C34H61O9P (644.4053)


PA(13:0/18:2(10E,12Z)+=O(9)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(13:0/18:2(10E,12Z)+=O(9)), in particular, consists of one chain of one tridecanoyl at the C-1 position and one chain of 9-oxo-octadecadienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(18:2(10E,12Z)+=O(9)/13:0)

[(2R)-3-{[(10E,12Z)-9-oxooctadeca-10,12-dienoyl]oxy}-2-(tridecanoyloxy)propoxy]phosphonic acid

C34H61O9P (644.4053)


PA(18:2(10E,12Z)+=O(9)/13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:2(10E,12Z)+=O(9)/13:0), in particular, consists of one chain of one 9-oxo-octadecadienoyl at the C-1 position and one chain of tridecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(13:0/18:2(9Z,11E)+=O(13))

[(2R)-2-{[(9Z,11E)-13-oxooctadeca-9,11-dienoyl]oxy}-3-(tridecanoyloxy)propoxy]phosphonic acid

C34H61O9P (644.4053)


PA(13:0/18:2(9Z,11E)+=O(13)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(13:0/18:2(9Z,11E)+=O(13)), in particular, consists of one chain of one tridecanoyl at the C-1 position and one chain of 13-oxo-octadecadienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(18:2(9Z,11E)+=O(13)/13:0)

[(2R)-3-{[(9Z,11E)-13-oxooctadeca-9,11-dienoyl]oxy}-2-(tridecanoyloxy)propoxy]phosphonic acid

C34H61O9P (644.4053)


PA(18:2(9Z,11E)+=O(13)/13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:2(9Z,11E)+=O(13)/13:0), in particular, consists of one chain of one 13-oxo-octadecadienoyl at the C-1 position and one chain of tridecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(13:0/18:3(10,12,15)-OH(9))

[(2R)-2-{[(10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoyl]oxy}-3-(tridecanoyloxy)propoxy]phosphonic acid

C34H61O9P (644.4053)


PA(13:0/18:3(10,12,15)-OH(9)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(13:0/18:3(10,12,15)-OH(9)), in particular, consists of one chain of one tridecanoyl at the C-1 position and one chain of 9-hydroxyoctadecatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(18:3(10,12,15)-OH(9)/13:0)

[(2R)-3-{[(10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoyl]oxy}-2-(tridecanoyloxy)propoxy]phosphonic acid

C34H61O9P (644.4053)


PA(18:3(10,12,15)-OH(9)/13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:3(10,12,15)-OH(9)/13:0), in particular, consists of one chain of one 9-hydroxyoctadecatrienoyl at the C-1 position and one chain of tridecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(13:0/18:3(9,11,15)-OH(13))

[(2R)-2-{[(9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoyl]oxy}-3-(tridecanoyloxy)propoxy]phosphonic acid

C34H61O9P (644.4053)


PA(13:0/18:3(9,11,15)-OH(13)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(13:0/18:3(9,11,15)-OH(13)), in particular, consists of one chain of one tridecanoyl at the C-1 position and one chain of 13-hydroxyoctadecatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(18:3(9,11,15)-OH(13)/13:0)

[(2R)-3-{[(9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoyl]oxy}-2-(tridecanoyloxy)propoxy]phosphonic acid

C34H61O9P (644.4053)


PA(18:3(9,11,15)-OH(13)/13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:3(9,11,15)-OH(13)/13:0), in particular, consists of one chain of one 13-hydroxyoctadecatrienoyl at the C-1 position and one chain of tridecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(a-13:0/18:2(10E,12Z)+=O(9))

[(2R)-3-[(10-methyldodecanoyl)oxy]-2-{[(10E,12Z)-9-oxooctadeca-10,12-dienoyl]oxy}propoxy]phosphonic acid

C34H61O9P (644.4053)


PA(a-13:0/18:2(10E,12Z)+=O(9)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(a-13:0/18:2(10E,12Z)+=O(9)), in particular, consists of one chain of one 10-methyldodecanoyl at the C-1 position and one chain of 9-oxo-octadecadienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(18:2(10E,12Z)+=O(9)/a-13:0)

[(2R)-2-[(10-methyldodecanoyl)oxy]-3-{[(10E,12Z)-9-oxooctadeca-10,12-dienoyl]oxy}propoxy]phosphonic acid

C34H61O9P (644.4053)


PA(18:2(10E,12Z)+=O(9)/a-13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:2(10E,12Z)+=O(9)/a-13:0), in particular, consists of one chain of one 9-oxo-octadecadienoyl at the C-1 position and one chain of 10-methyldodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(a-13:0/18:2(9Z,11E)+=O(13))

[(2R)-3-[(10-methyldodecanoyl)oxy]-2-{[(9Z,11E)-13-oxooctadeca-9,11-dienoyl]oxy}propoxy]phosphonic acid

C34H61O9P (644.4053)


PA(a-13:0/18:2(9Z,11E)+=O(13)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(a-13:0/18:2(9Z,11E)+=O(13)), in particular, consists of one chain of one 10-methyldodecanoyl at the C-1 position and one chain of 13-oxo-octadecadienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(18:2(9Z,11E)+=O(13)/a-13:0)

[(2R)-2-[(10-methyldodecanoyl)oxy]-3-{[(9Z,11E)-13-oxooctadeca-9,11-dienoyl]oxy}propoxy]phosphonic acid

C34H61O9P (644.4053)


PA(18:2(9Z,11E)+=O(13)/a-13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:2(9Z,11E)+=O(13)/a-13:0), in particular, consists of one chain of one 13-oxo-octadecadienoyl at the C-1 position and one chain of 10-methyldodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(a-13:0/18:3(10,12,15)-OH(9))

[(2R)-2-{[(10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoyl]oxy}-3-[(10-methyldodecanoyl)oxy]propoxy]phosphonic acid

C34H61O9P (644.4053)


PA(a-13:0/18:3(10,12,15)-OH(9)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(a-13:0/18:3(10,12,15)-OH(9)), in particular, consists of one chain of one 10-methyldodecanoyl at the C-1 position and one chain of 9-hydroxyoctadecatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(18:3(10,12,15)-OH(9)/a-13:0)

[(2R)-3-{[(10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoyl]oxy}-2-[(10-methyldodecanoyl)oxy]propoxy]phosphonic acid

C34H61O9P (644.4053)


PA(18:3(10,12,15)-OH(9)/a-13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:3(10,12,15)-OH(9)/a-13:0), in particular, consists of one chain of one 9-hydroxyoctadecatrienoyl at the C-1 position and one chain of 10-methyldodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(a-13:0/18:3(9,11,15)-OH(13))

[(2R)-2-{[(9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoyl]oxy}-3-[(10-methyldodecanoyl)oxy]propoxy]phosphonic acid

C34H61O9P (644.4053)


PA(a-13:0/18:3(9,11,15)-OH(13)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(a-13:0/18:3(9,11,15)-OH(13)), in particular, consists of one chain of one 10-methyldodecanoyl at the C-1 position and one chain of 13-hydroxyoctadecatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(18:3(9,11,15)-OH(13)/a-13:0)

[(2R)-3-{[(9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoyl]oxy}-2-[(10-methyldodecanoyl)oxy]propoxy]phosphonic acid

C34H61O9P (644.4053)


PA(18:3(9,11,15)-OH(13)/a-13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:3(9,11,15)-OH(13)/a-13:0), in particular, consists of one chain of one 13-hydroxyoctadecatrienoyl at the C-1 position and one chain of 10-methyldodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-13:0/18:2(10E,12Z)+=O(9))

[(2R)-3-[(11-methyldodecanoyl)oxy]-2-{[(10E,12Z)-9-oxooctadeca-10,12-dienoyl]oxy}propoxy]phosphonic acid

C34H61O9P (644.4053)


PA(i-13:0/18:2(10E,12Z)+=O(9)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-13:0/18:2(10E,12Z)+=O(9)), in particular, consists of one chain of one 11-methyldodecanoyl at the C-1 position and one chain of 9-oxo-octadecadienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(18:2(10E,12Z)+=O(9)/i-13:0)

[(2R)-2-[(11-methyldodecanoyl)oxy]-3-{[(10E,12Z)-9-oxooctadeca-10,12-dienoyl]oxy}propoxy]phosphonic acid

C34H61O9P (644.4053)


PA(18:2(10E,12Z)+=O(9)/i-13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:2(10E,12Z)+=O(9)/i-13:0), in particular, consists of one chain of one 9-oxo-octadecadienoyl at the C-1 position and one chain of 11-methyldodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-13:0/18:2(9Z,11E)+=O(13))

[(2R)-3-[(11-methyldodecanoyl)oxy]-2-{[(9Z,11E)-13-oxooctadeca-9,11-dienoyl]oxy}propoxy]phosphonic acid

C34H61O9P (644.4053)


PA(i-13:0/18:2(9Z,11E)+=O(13)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-13:0/18:2(9Z,11E)+=O(13)), in particular, consists of one chain of one 11-methyldodecanoyl at the C-1 position and one chain of 13-oxo-octadecadienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(18:2(9Z,11E)+=O(13)/i-13:0)

[(2R)-2-[(11-methyldodecanoyl)oxy]-3-{[(9Z,11E)-13-oxooctadeca-9,11-dienoyl]oxy}propoxy]phosphonic acid

C34H61O9P (644.4053)


PA(18:2(9Z,11E)+=O(13)/i-13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:2(9Z,11E)+=O(13)/i-13:0), in particular, consists of one chain of one 13-oxo-octadecadienoyl at the C-1 position and one chain of 11-methyldodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-13:0/18:3(10,12,15)-OH(9))

[(2R)-2-{[(10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoyl]oxy}-3-[(11-methyldodecanoyl)oxy]propoxy]phosphonic acid

C34H61O9P (644.4053)


PA(i-13:0/18:3(10,12,15)-OH(9)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-13:0/18:3(10,12,15)-OH(9)), in particular, consists of one chain of one 11-methyldodecanoyl at the C-1 position and one chain of 9-hydroxyoctadecatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(18:3(10,12,15)-OH(9)/i-13:0)

[(2R)-3-{[(10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoyl]oxy}-2-[(11-methyldodecanoyl)oxy]propoxy]phosphonic acid

C34H61O9P (644.4053)


PA(18:3(10,12,15)-OH(9)/i-13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:3(10,12,15)-OH(9)/i-13:0), in particular, consists of one chain of one 9-hydroxyoctadecatrienoyl at the C-1 position and one chain of 11-methyldodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-13:0/18:3(9,11,15)-OH(13))

[(2R)-2-{[(9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoyl]oxy}-3-[(11-methyldodecanoyl)oxy]propoxy]phosphonic acid

C34H61O9P (644.4053)


PA(i-13:0/18:3(9,11,15)-OH(13)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-13:0/18:3(9,11,15)-OH(13)), in particular, consists of one chain of one 11-methyldodecanoyl at the C-1 position and one chain of 13-hydroxyoctadecatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(18:3(9,11,15)-OH(13)/i-13:0)

[(2R)-3-{[(9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoyl]oxy}-2-[(11-methyldodecanoyl)oxy]propoxy]phosphonic acid

C34H61O9P (644.4053)


PA(18:3(9,11,15)-OH(13)/i-13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:3(9,11,15)-OH(13)/i-13:0), in particular, consists of one chain of one 13-hydroxyoctadecatrienoyl at the C-1 position and one chain of 11-methyldodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   
   
   

6-Formyl-2,3,3a,4,5,8,9,11a-octahydro-10-(hydroxymethyl)-3-methylene-4-(2-methyl-1-oxobutoxy)-2-oxocyclodeca[b]furan-5-yl ester octadecanoic acid

6-Formyl-2,3,3a,4,5,8,9,11a-octahydro-10-(hydroxymethyl)-3-methylene-4-(2-methyl-1-oxobutoxy)-2-oxocyclodeca[b]furan-5-yl ester octadecanoic acid

C38H60O8 (644.4288)


   

Khekadaengoside H

Khekadaengoside H

C36H52O10 (644.356)


   
   

Antibiotic BU 3292TA

Antibiotic BU 3292TA

C32H48N6O8 (644.3533)


   
   
   

(25S,3S)-(+)-12alpha-hydroxy-3alpha-(3-hydroxy-4-methoxycarbonyl-3-methylbutyryloxy)-24-methyllanosta-8,24(31)-dien-26-oic acid

(25S,3S)-(+)-12alpha-hydroxy-3alpha-(3-hydroxy-4-methoxycarbonyl-3-methylbutyryloxy)-24-methyllanosta-8,24(31)-dien-26-oic acid

C38H60O8 (644.4288)


   

Nilgherron A

Nilgherron A

C40H52O7 (644.3713)


   

3alpha-acetoxylanosta-8,24(31)-dien-21-oic acid 21-O-beta-D-xylopyranoside|fomitoside G

3alpha-acetoxylanosta-8,24(31)-dien-21-oic acid 21-O-beta-D-xylopyranoside|fomitoside G

C38H60O8 (644.4288)


   

3alpha-(3-butylcarboxyacetoxy)oxepanoquercinic acid C

3alpha-(3-butylcarboxyacetoxy)oxepanoquercinic acid C

C38H60O8 (644.4288)


   

20-O-(2,3-dimethylbutanoyl)-13-O-dodecanoylingenol

20-O-(2,3-dimethylbutanoyl)-13-O-dodecanoylingenol

C38H60O8 (644.4288)


   

Fucoxanthin

Fucoxanthin

C41H56O6 (644.4077)


   

25-anhydrocimigenol-3-O-[3-O-acetyl-alpha-L-arabinopyranoside]

25-anhydrocimigenol-3-O-[3-O-acetyl-alpha-L-arabinopyranoside]

C37H56O9 (644.3924)


   

onchidionol

onchidionol

C37H56O9 (644.3924)


   

3-O-(2,3-Dimethylbutanoyl)-13-O-dodecanoylingenol

3-O-(2,3-Dimethylbutanoyl)-13-O-dodecanoylingenol

C38H60O8 (644.4288)


   

16beta:23-epoxy-12beta-acetoxy-22,23-didehydro-24-one-25-hydro-9,19-cyclolanostane-3-O-beta-D-xylopyranoside|asiaticoside A

16beta:23-epoxy-12beta-acetoxy-22,23-didehydro-24-one-25-hydro-9,19-cyclolanostane-3-O-beta-D-xylopyranoside|asiaticoside A

C37H56O9 (644.3924)


   

13-O-dodecanoyl-20-O-hexanoylingenol|13-Oxyingenol-13-dodecanoate-20-hexanoate

13-O-dodecanoyl-20-O-hexanoylingenol|13-Oxyingenol-13-dodecanoate-20-hexanoate

C38H60O8 (644.4288)


   

12-O-Hexadecanoyl-phorbol-13-acetate|12-O-n-Hexadecanoyl-phorbol-13-acetat|Cocarcinogen A4|Phorbol-12-palmitate-13-acetate

12-O-Hexadecanoyl-phorbol-13-acetate|12-O-n-Hexadecanoyl-phorbol-13-acetat|Cocarcinogen A4|Phorbol-12-palmitate-13-acetate

C38H60O8 (644.4288)


   

10,21beta-epoxy-1-methyl-9-(21alpha-methyl-(20alphaH)-20,21-dihydro-19-nor-alstophyllan-18-yl)-sarpagan-17-ol|9,10,11,12,18,18,18,11,12-Decadeutero-macralstonidin|Macralstonidin|macralstonidine

10,21beta-epoxy-1-methyl-9-(21alpha-methyl-(20alphaH)-20,21-dihydro-19-nor-alstophyllan-18-yl)-sarpagan-17-ol|9,10,11,12,18,18,18,11,12-Decadeutero-macralstonidin|Macralstonidin|macralstonidine

C41H48N4O3 (644.3726)


   

Welensalifactor F1

Welensalifactor F1

C38H60O8 (644.4288)


   

25-anhydrocimicigenol-3-O-beta-D-(2-O-acetyl)xylopyranoside|25-anhydrocimigenol-3-O-[2?-O-acetyl]-beta-D-xylopyranoside

25-anhydrocimicigenol-3-O-beta-D-(2-O-acetyl)xylopyranoside|25-anhydrocimigenol-3-O-[2?-O-acetyl]-beta-D-xylopyranoside

C37H56O9 (644.3924)


   

Prostaglandin A2-biotin

Prostaglandin A2-biotin

C35H56N4O5S (644.3971)


   

Lys Arg Arg Trp

(2S)-2-[(2S)-5-carbamimidamido-2-[(2S)-5-carbamimidamido-2-[(2S)-2,6-diaminohexanamido]pentanamido]pentanamido]-3-(1H-indol-3-yl)propanoic acid

C29H48N12O5 (644.387)


   

Lys Arg Trp Arg

(2S)-5-carbamimidamido-2-[(2S)-2-[(2S)-5-carbamimidamido-2-[(2S)-2,6-diaminohexanamido]pentanamido]-3-(1H-indol-3-yl)propanamido]pentanoic acid

C29H48N12O5 (644.387)


   

Lys Trp Arg Arg

(2S)-5-carbamimidamido-2-[(2S)-5-carbamimidamido-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-(1H-indol-3-yl)propanamido]pentanamido]pentanoic acid

C29H48N12O5 (644.387)


   

Gln Arg Arg Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-carbamoylbutanamido]-5-carbamimidamidopentanamido]-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanoic acid

C28H44N12O6 (644.3507)


   

Gln Arg Trp Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-carbamoylbutanamido]-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanoic acid

C28H44N12O6 (644.3507)


   

Gln Trp Arg Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-carbamoylbutanamido]-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanamido]-5-carbamimidamidopentanoic acid

C28H44N12O6 (644.3507)


   

Arg Lys Arg Trp

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-5-carbamimidamidopentanamido]hexanamido]-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanoic acid

C29H48N12O5 (644.387)


   

Arg Lys Trp Arg

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-5-carbamimidamidopentanamido]hexanamido]-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanoic acid

C29H48N12O5 (644.387)


   

Arg Gln Arg Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-4-carbamoylbutanamido]-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanoic acid

C28H44N12O6 (644.3507)


   

Arg Gln Trp Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-4-carbamoylbutanamido]-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanoic acid

C28H44N12O6 (644.3507)


   

Arg Arg Lys Trp

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-5-carbamimidamidopentanamido]hexanamido]-3-(1H-indol-3-yl)propanoic acid

C29H48N12O5 (644.387)


   

Arg Arg Gln Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-5-carbamimidamidopentanamido]-4-carbamoylbutanamido]-3-(1H-indol-3-yl)propanoic acid

C28H44N12O6 (644.3507)


   

Arg Arg Trp Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanamido]hexanoic acid

C29H48N12O5 (644.387)


   

Arg Arg Trp Gln

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanamido]-4-carbamoylbutanoic acid

C28H44N12O6 (644.3507)


   

Arg Trp Lys Arg

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanamido]hexanamido]-5-carbamimidamidopentanoic acid

C29H48N12O5 (644.387)


   

Arg Trp Gln Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanamido]-4-carbamoylbutanamido]-5-carbamimidamidopentanoic acid

C28H44N12O6 (644.3507)


   

Arg Trp Arg Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanamido]hexanoic acid

C29H48N12O5 (644.387)


   

Arg Trp Arg Gln

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanamido]-4-carbamoylbutanoic acid

C28H44N12O6 (644.3507)


   

Trp Lys Arg Arg

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]hexanamido]-5-carbamimidamidopentanamido]-5-carbamimidamidopentanoic acid

C29H48N12O5 (644.387)


   

Trp Gln Arg Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-4-carbamoylbutanamido]-5-carbamimidamidopentanamido]-5-carbamimidamidopentanoic acid

C28H44N12O6 (644.3507)


   

Trp Arg Lys Arg

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanamido]hexanamido]-5-carbamimidamidopentanoic acid

C29H48N12O5 (644.387)


   

Trp Arg Gln Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanamido]-4-carbamoylbutanamido]-5-carbamimidamidopentanoic acid

C28H44N12O6 (644.3507)


   

Trp Arg Arg Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanamido]-5-carbamimidamidopentanamido]hexanoic acid

C29H48N12O5 (644.387)


   

Trp Arg Arg Gln

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanamido]-5-carbamimidamidopentanamido]-4-carbamoylbutanoic acid

C28H44N12O6 (644.3507)


   

LRMLL

Leu Arg Met Leu Leu

C29H56N8O6S (644.4043)


   

PA(12:0/20:2(11Z,14Z))

1-dodecanoyl-2-(11Z,14Z-eicosadienoyl)-glycero-3-phosphate

C35H65O8P (644.4417)


   

PA(14:1(9Z)/18:1(9Z))

1-(9Z-tetradecenoyl)-2-(9Z-octadecenoyl)-glycero-3-phosphate

C35H65O8P (644.4417)


   

PA(15:0/17:2(9Z,12Z))

1-pentadecanoyl-2-(9Z,12Z-heptadecadienoyl)-glycero-3-phosphate

C35H65O8P (644.4417)


   

PA(15:1(9Z)/17:1(9Z))

1-(9Z-pentadecenoyl)-2-(9Z-heptadecenoyl)-glycero-3-phosphate

C35H65O8P (644.4417)


   

PA(17:1(9Z)/15:1(9Z))

1-(9Z-heptadecenoyl)-2-(9Z-pentadecenoyl)-glycero-3-phosphate

C35H65O8P (644.4417)


   

PA(17:2(9Z,12Z)/15:0)

1-(9Z,12Z-heptadecadienoyl)-2-pentadecanoyl-glycero-3-phosphate

C35H65O8P (644.4417)


   

PA(18:1(9Z)/14:1(9Z))

1-(9Z-octadecenoyl)-2-(9Z-tetradecenoyl)-glycero-3-phosphate

C35H65O8P (644.4417)


   

PA(18:2(9Z,12Z)/14:0)

1-(9Z,12Z-octadecadienoyl)-2-tetradecanoyl-glycero-3-phosphate

C35H65O8P (644.4417)


   

PA(20:2(11Z,14Z)/12:0)

1-(11Z,14Z-eicosadienoyl)-2-dodecanoyl-glycero-3-phosphate

C35H65O8P (644.4417)


   

PA(14:0/18:2(9Z,12Z))

1-tetradecanoyl-2-(9Z,12Z-octadecadienoyl)-glycero-3-phosphate

C35H65O8P (644.4417)


   

PA(16:1(9Z)/16:1(9Z))

1,2-di-(9Z-hexadecenoyl)-sn-glycero-3-phosphate

C35H65O8P (644.4417)


   

O-Methylganoderic acid O

(2E)-5-(acetyloxy)-6-[5,12-bis(acetyloxy)-9-methoxy-2,6,6,11,15-pentamethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-1(10)-en-14-yl]-2-methylhept-2-enoic acid

C37H56O9 (644.3924)


   

8-iso Prostaglandin A2-biotin

8-iso Prostaglandin A2-biotin

C35H56N4O5S (644.3971)


   

PA 32:2

1-(9Z,12Z-heptadecadienoyl)-2-pentadecanoyl-glycero-3-phosphate

C35H65O8P (644.4417)


   

OKODA-PA

1-(9Z-octadecenoyl)-2-(9,12-dioxo-10E-dodecenoyl)-sn-glycero-3-phosphate

C33H57O10P (644.3689)


   

hellebrigenol-3-(14-hydroxymyristate)

3beta,5beta,14beta,19-tetrahydroxy-bufa-20,22-dienolide-3beta-yl-14-hydroxy-tetradecanoate

C38H60O8 (644.4288)


   

1beta-hydroxytelocinobufagin-3-(14-hydroxymyristate)

1beta,3beta,5beta,14beta-tetrahydroxy-bufa-20,22-dienolide-3beta-yl-14-hydroxy-tetradecanoate

C38H60O8 (644.4288)


   

3,3-Diethanoyloxyisorenieratene

3,3-Diethaynoyloxy-phi,phi-Carotene

C44H52O4 (644.3865)


   

Bis(1,4-phenylene)-34-crown 10-Ether

Bis(1,4-phenylene)-34-crown 10-Ether

C36H52O10 (644.356)


   

t-Boc-N-amido-PEG11-amine

t-Boc-N-amido-PEG11-amine

C29H60N2O13 (644.4095)


   
   

Adipic acid ethylene glycol,isodecyl alcohol,isooctyl alcohol,phthalic anhydride polymer

Adipic acid ethylene glycol,isodecyl alcohol,isooctyl alcohol,phthalic anhydride polymer

C34H60O11 (644.4135)


   
   

6-(6-{3-[(Progesterone-4-yl)thiopropionyl]aminohexanoyl}amino)hexanoic acid

6-(6-{3-[(Progesterone-4-yl)thiopropionyl]aminohexanoyl}amino)hexanoic acid

C36H56N2O6S (644.3859)


   

(2R)-2-[(9Z)-hexadec-9-enoyloxy]-3-(palmitoyloxy)propyl phosphate

(2R)-2-[(9Z)-hexadec-9-enoyloxy]-3-(palmitoyloxy)propyl phosphate

C35H65O8P-2 (644.4417)


   

PA(13:0/18:2(10E,12Z)+=O(9))

PA(13:0/18:2(10E,12Z)+=O(9))

C34H61O9P (644.4053)


   

PA(18:2(10E,12Z)+=O(9)/13:0)

PA(18:2(10E,12Z)+=O(9)/13:0)

C34H61O9P (644.4053)


   

PA(13:0/18:2(9Z,11E)+=O(13))

PA(13:0/18:2(9Z,11E)+=O(13))

C34H61O9P (644.4053)


   

PA(18:2(9Z,11E)+=O(13)/13:0)

PA(18:2(9Z,11E)+=O(13)/13:0)

C34H61O9P (644.4053)


   

PA(a-13:0/18:2(10E,12Z)+=O(9))

PA(a-13:0/18:2(10E,12Z)+=O(9))

C34H61O9P (644.4053)


   

PA(18:2(10E,12Z)+=O(9)/a-13:0)

PA(18:2(10E,12Z)+=O(9)/a-13:0)

C34H61O9P (644.4053)


   

PA(a-13:0/18:2(9Z,11E)+=O(13))

PA(a-13:0/18:2(9Z,11E)+=O(13))

C34H61O9P (644.4053)


   

PA(18:2(9Z,11E)+=O(13)/a-13:0)

PA(18:2(9Z,11E)+=O(13)/a-13:0)

C34H61O9P (644.4053)


   

PA(i-13:0/18:2(10E,12Z)+=O(9))

PA(i-13:0/18:2(10E,12Z)+=O(9))

C34H61O9P (644.4053)


   

PA(18:2(10E,12Z)+=O(9)/i-13:0)

PA(18:2(10E,12Z)+=O(9)/i-13:0)

C34H61O9P (644.4053)


   

PA(i-13:0/18:2(9Z,11E)+=O(13))

PA(i-13:0/18:2(9Z,11E)+=O(13))

C34H61O9P (644.4053)


   

PA(18:2(9Z,11E)+=O(13)/i-13:0)

PA(18:2(9Z,11E)+=O(13)/i-13:0)

C34H61O9P (644.4053)


   

[(2R)-1-phosphonooxy-3-tridecanoyloxypropan-2-yl] (10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoate

[(2R)-1-phosphonooxy-3-tridecanoyloxypropan-2-yl] (10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoate

C34H61O9P (644.4053)


   

[(2R)-3-phosphonooxy-2-tridecanoyloxypropyl] (10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoate

[(2R)-3-phosphonooxy-2-tridecanoyloxypropyl] (10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoate

C34H61O9P (644.4053)


   

[(2R)-1-phosphonooxy-3-tridecanoyloxypropan-2-yl] (9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoate

[(2R)-1-phosphonooxy-3-tridecanoyloxypropan-2-yl] (9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoate

C34H61O9P (644.4053)


   

[(2R)-3-phosphonooxy-2-tridecanoyloxypropyl] (9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoate

[(2R)-3-phosphonooxy-2-tridecanoyloxypropyl] (9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoate

C34H61O9P (644.4053)


   

PA(a-13:0/18:3(10,12,15)-OH(9))

PA(a-13:0/18:3(10,12,15)-OH(9))

C34H61O9P (644.4053)


   

PA(18:3(10,12,15)-OH(9)/a-13:0)

PA(18:3(10,12,15)-OH(9)/a-13:0)

C34H61O9P (644.4053)


   

PA(a-13:0/18:3(9,11,15)-OH(13))

PA(a-13:0/18:3(9,11,15)-OH(13))

C34H61O9P (644.4053)


   

PA(18:3(9,11,15)-OH(13)/a-13:0)

PA(18:3(9,11,15)-OH(13)/a-13:0)

C34H61O9P (644.4053)


   

PA(i-13:0/18:3(10,12,15)-OH(9))

PA(i-13:0/18:3(10,12,15)-OH(9))

C34H61O9P (644.4053)


   

PA(18:3(10,12,15)-OH(9)/i-13:0)

PA(18:3(10,12,15)-OH(9)/i-13:0)

C34H61O9P (644.4053)


   

PA(i-13:0/18:3(9,11,15)-OH(13))

PA(i-13:0/18:3(9,11,15)-OH(13))

C34H61O9P (644.4053)


   

PA(18:3(9,11,15)-OH(13)/i-13:0)

PA(18:3(9,11,15)-OH(13)/i-13:0)

C34H61O9P (644.4053)


   

PA(10:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R))

PA(10:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R))

C33H57O10P (644.3689)


   

PA(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/10:0)

PA(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/10:0)

C33H57O10P (644.3689)


   

PA(10:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S))

PA(10:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S))

C33H57O10P (644.3689)


   

PA(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/10:0)

PA(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/10:0)

C33H57O10P (644.3689)


   

PA(10:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R))

PA(10:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R))

C33H57O10P (644.3689)


   

PA(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/10:0)

PA(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/10:0)

C33H57O10P (644.3689)


   

AcChaArgDiscMetNH2

AcChaArgDiscMetNH2

C31H48N8O5S (644.3468)


   

1-Oleoyl-2-myristoyl-sn-glycero-3-phosphate(2-)

1-Oleoyl-2-myristoyl-sn-glycero-3-phosphate(2-)

C35H65O8P-2 (644.4417)


   

1-Myristoyl-2-oleoyl-sn-glycero-3-phosphate(2-)

1-Myristoyl-2-oleoyl-sn-glycero-3-phosphate(2-)

C35H65O8P-2 (644.4417)


   

archaeal dolichyl N-acetyl-alpha-D-glucosaminyl phosphate(1-)

archaeal dolichyl N-acetyl-alpha-D-glucosaminyl phosphate(1-)

C33H59NO9P- (644.3927)


   

[2-[(Z)-hexadec-9-enoyl]oxy-3-phosphonooxypropyl] (Z)-hexadec-9-enoate

[2-[(Z)-hexadec-9-enoyl]oxy-3-phosphonooxypropyl] (Z)-hexadec-9-enoate

C35H65O8P (644.4417)


   

NAGlySer 16:3/16:2

NAGlySer 16:3/16:2

C37H60N2O7 (644.44)


   

NAGlySer 16:2/16:3

NAGlySer 16:2/16:3

C37H60N2O7 (644.44)


   

NAGlySer 18:5/14:0

NAGlySer 18:5/14:0

C37H60N2O7 (644.44)


   

NAGlySer 16:4/16:1

NAGlySer 16:4/16:1

C37H60N2O7 (644.44)


   

NAGlySer 18:4/14:1

NAGlySer 18:4/14:1

C37H60N2O7 (644.44)


   

NAGlySer 22:5/10:0

NAGlySer 22:5/10:0

C37H60N2O7 (644.44)


   

NAGlySer 20:5/12:0

NAGlySer 20:5/12:0

C37H60N2O7 (644.44)


   

NAGlySer 10:0/22:5

NAGlySer 10:0/22:5

C37H60N2O7 (644.44)


   

[1-decoxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate

[1-decoxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate

C34H61O9P (644.4053)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoxy]propan-2-yl] decanoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoxy]propan-2-yl] decanoate

C34H61O9P (644.4053)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoxy]propan-2-yl] dodecanoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoxy]propan-2-yl] dodecanoate

C34H61O9P (644.4053)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-dodecoxypropan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-dodecoxypropan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate

C34H61O9P (644.4053)


   
   

PMeOH 13:1_18:1

PMeOH 13:1_18:1

C35H65O8P (644.4417)


   

PEtOH 14:1_16:1

PEtOH 14:1_16:1

C35H65O8P (644.4417)


   

PEtOH 15:1_15:1

PEtOH 15:1_15:1

C35H65O8P (644.4417)


   

PEtOH 13:0_17:2

PEtOH 13:0_17:2

C35H65O8P (644.4417)


   

PMeOH 14:0_17:2

PMeOH 14:0_17:2

C35H65O8P (644.4417)


   

PMeOH 14:1_17:1

PMeOH 14:1_17:1

C35H65O8P (644.4417)


   

PEtOH 14:0_16:2

PEtOH 14:0_16:2

C35H65O8P (644.4417)


   

PEtOH 12:0_18:2

PEtOH 12:0_18:2

C35H65O8P (644.4417)


   

PMeOH 15:1_16:1

PMeOH 15:1_16:1

C35H65O8P (644.4417)


   

PMeOH 15:0_16:2

PMeOH 15:0_16:2

C35H65O8P (644.4417)


   

PEtOH 13:1_17:1

PEtOH 13:1_17:1

C35H65O8P (644.4417)


   

PMeOH 13:0_18:2

PMeOH 13:0_18:2

C35H65O8P (644.4417)


   

PMeOH 12:0_19:2

PMeOH 12:0_19:2

C35H65O8P (644.4417)


   

[1-hydroxy-3-[hydroxy-(3-hydroxy-2-propanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoate

[1-hydroxy-3-[hydroxy-(3-hydroxy-2-propanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoate

C33H57O10P (644.3689)


   

[1-hydroxy-3-[hydroxy-(3-hydroxy-2-pentanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate

[1-hydroxy-3-[hydroxy-(3-hydroxy-2-pentanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate

C33H57O10P (644.3689)


   

[1-hydroxy-3-[hydroxy-(3-hydroxy-2-nonanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate

[1-hydroxy-3-[hydroxy-(3-hydroxy-2-nonanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate

C33H57O10P (644.3689)


   

[1-[(2-heptanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate

[1-[(2-heptanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate

C33H57O10P (644.3689)


   

[1-hydroxy-3-[hydroxy-(3-hydroxy-2-undecanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate

[1-hydroxy-3-[hydroxy-(3-hydroxy-2-undecanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate

C33H57O10P (644.3689)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-propanoyloxypropan-2-yl] (12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-propanoyloxypropan-2-yl] (12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoate

C33H57O10P (644.3689)


   

(1-hexanoyloxy-3-phosphonooxypropan-2-yl) (15Z,18Z)-hexacosa-15,18-dienoate

(1-hexanoyloxy-3-phosphonooxypropan-2-yl) (15Z,18Z)-hexacosa-15,18-dienoate

C35H65O8P (644.4417)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-nonanoyloxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-nonanoyloxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate

C33H57O10P (644.3689)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-pentanoyloxypropan-2-yl] (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-pentanoyloxypropan-2-yl] (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate

C33H57O10P (644.3689)


   

(1-octanoyloxy-3-phosphonooxypropan-2-yl) (13Z,16Z)-tetracosa-13,16-dienoate

(1-octanoyloxy-3-phosphonooxypropan-2-yl) (13Z,16Z)-tetracosa-13,16-dienoate

C35H65O8P (644.4417)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-heptanoyloxypropan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-heptanoyloxypropan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate

C33H57O10P (644.3689)


   

[1-[(Z)-pentadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (Z)-heptadec-9-enoate

[1-[(Z)-pentadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (Z)-heptadec-9-enoate

C35H65O8P (644.4417)


   

[1-phosphonooxy-3-[(Z)-tridec-9-enoyl]oxypropan-2-yl] (Z)-nonadec-9-enoate

[1-phosphonooxy-3-[(Z)-tridec-9-enoyl]oxypropan-2-yl] (Z)-nonadec-9-enoate

C35H65O8P (644.4417)


   

[2-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxy-3-phosphonooxypropyl] hexadecanoate

[2-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxy-3-phosphonooxypropyl] hexadecanoate

C35H65O8P (644.4417)


   

[1-phosphonooxy-3-[(Z)-tetradec-9-enoyl]oxypropan-2-yl] (Z)-octadec-9-enoate

[1-phosphonooxy-3-[(Z)-tetradec-9-enoyl]oxypropan-2-yl] (Z)-octadec-9-enoate

C35H65O8P (644.4417)


   

(1-phosphonooxy-3-tridecanoyloxypropan-2-yl) (9Z,12Z)-nonadeca-9,12-dienoate

(1-phosphonooxy-3-tridecanoyloxypropan-2-yl) (9Z,12Z)-nonadeca-9,12-dienoate

C35H65O8P (644.4417)


   

(1-phosphonooxy-3-undecanoyloxypropan-2-yl) (11Z,14Z)-henicosa-11,14-dienoate

(1-phosphonooxy-3-undecanoyloxypropan-2-yl) (11Z,14Z)-henicosa-11,14-dienoate

C35H65O8P (644.4417)


   

(1-phosphonooxy-3-tetradecanoyloxypropan-2-yl) (9Z,12Z)-octadeca-9,12-dienoate

(1-phosphonooxy-3-tetradecanoyloxypropan-2-yl) (9Z,12Z)-octadeca-9,12-dienoate

C35H65O8P (644.4417)


   

(1-decanoyloxy-3-phosphonooxypropan-2-yl) (13Z,16Z)-docosa-13,16-dienoate

(1-decanoyloxy-3-phosphonooxypropan-2-yl) (13Z,16Z)-docosa-13,16-dienoate

C35H65O8P (644.4417)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-undecanoyloxypropan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-undecanoyloxypropan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate

C33H57O10P (644.3689)


   

(1-pentadecanoyloxy-3-phosphonooxypropan-2-yl) (9Z,12Z)-heptadeca-9,12-dienoate

(1-pentadecanoyloxy-3-phosphonooxypropan-2-yl) (9Z,12Z)-heptadeca-9,12-dienoate

C35H65O8P (644.4417)


   

(1-dodecanoyloxy-3-phosphonooxypropan-2-yl) (11Z,14Z)-icosa-11,14-dienoate

(1-dodecanoyloxy-3-phosphonooxypropan-2-yl) (11Z,14Z)-icosa-11,14-dienoate

C35H65O8P (644.4417)


   

[(2R)-2-[(E)-hexadec-9-enoyl]oxy-3-phosphonooxypropyl] (E)-hexadec-9-enoate

[(2R)-2-[(E)-hexadec-9-enoyl]oxy-3-phosphonooxypropyl] (E)-hexadec-9-enoate

C35H65O8P (644.4417)


   

[(2R)-3-phosphonooxy-2-[(E)-tetradec-9-enoyl]oxypropyl] (E)-octadec-13-enoate

[(2R)-3-phosphonooxy-2-[(E)-tetradec-9-enoyl]oxypropyl] (E)-octadec-13-enoate

C35H65O8P (644.4417)


   

[(2R)-2-dodecanoyloxy-3-phosphonooxypropyl] (5E,8E)-icosa-5,8-dienoate

[(2R)-2-dodecanoyloxy-3-phosphonooxypropyl] (5E,8E)-icosa-5,8-dienoate

C35H65O8P (644.4417)


   

[(2R)-1-dodecanoyloxy-3-phosphonooxypropan-2-yl] (5E,8E)-icosa-5,8-dienoate

[(2R)-1-dodecanoyloxy-3-phosphonooxypropan-2-yl] (5E,8E)-icosa-5,8-dienoate

C35H65O8P (644.4417)


   

[(2R)-2-decanoyloxy-3-phosphonooxypropyl] (13E,16E)-docosa-13,16-dienoate

[(2R)-2-decanoyloxy-3-phosphonooxypropyl] (13E,16E)-docosa-13,16-dienoate

C35H65O8P (644.4417)


   

[(2R)-1-phosphonooxy-3-[(E)-tetradec-9-enoyl]oxypropan-2-yl] (E)-octadec-7-enoate

[(2R)-1-phosphonooxy-3-[(E)-tetradec-9-enoyl]oxypropan-2-yl] (E)-octadec-7-enoate

C35H65O8P (644.4417)


   

[(2R)-3-phosphonooxy-2-[(E)-tetradec-9-enoyl]oxypropyl] (E)-octadec-7-enoate

[(2R)-3-phosphonooxy-2-[(E)-tetradec-9-enoyl]oxypropyl] (E)-octadec-7-enoate

C35H65O8P (644.4417)


   

2-[[3-[(E)-dec-4-enoyl]oxy-2-[(4E,7E)-hexadeca-4,7-dienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[3-[(E)-dec-4-enoyl]oxy-2-[(4E,7E)-hexadeca-4,7-dienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C34H63NO8P+ (644.4291)


   

[(2R)-3-phosphonooxy-2-tetradecanoyloxypropyl] (9E,12E)-octadeca-9,12-dienoate

[(2R)-3-phosphonooxy-2-tetradecanoyloxypropyl] (9E,12E)-octadeca-9,12-dienoate

C35H65O8P (644.4417)


   

[(2R)-2-pentadecanoyloxy-3-phosphonooxypropyl] (9E,12E)-heptadeca-9,12-dienoate

[(2R)-2-pentadecanoyloxy-3-phosphonooxypropyl] (9E,12E)-heptadeca-9,12-dienoate

C35H65O8P (644.4417)


   

[(2R)-1-[(E)-pentadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (E)-heptadec-9-enoate

[(2R)-1-[(E)-pentadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (E)-heptadec-9-enoate

C35H65O8P (644.4417)


   

[(2R)-3-phosphonooxy-2-[(E)-tetradec-9-enoyl]oxypropyl] (E)-octadec-11-enoate

[(2R)-3-phosphonooxy-2-[(E)-tetradec-9-enoyl]oxypropyl] (E)-octadec-11-enoate

C35H65O8P (644.4417)


   

[(2R)-1-phosphonooxy-3-[(E)-tetradec-9-enoyl]oxypropan-2-yl] (E)-octadec-6-enoate

[(2R)-1-phosphonooxy-3-[(E)-tetradec-9-enoyl]oxypropan-2-yl] (E)-octadec-6-enoate

C35H65O8P (644.4417)


   

[(2R)-2-[(E)-hexadec-7-enoyl]oxy-3-phosphonooxypropyl] (E)-hexadec-7-enoate

[(2R)-2-[(E)-hexadec-7-enoyl]oxy-3-phosphonooxypropyl] (E)-hexadec-7-enoate

C35H65O8P (644.4417)


   

[(2R)-2-[(E)-hexadec-9-enoyl]oxy-3-phosphonooxypropyl] (E)-hexadec-7-enoate

[(2R)-2-[(E)-hexadec-9-enoyl]oxy-3-phosphonooxypropyl] (E)-hexadec-7-enoate

C35H65O8P (644.4417)


   

[(2R)-1-phosphonooxy-3-[(E)-tetradec-9-enoyl]oxypropan-2-yl] octadec-17-enoate

[(2R)-1-phosphonooxy-3-[(E)-tetradec-9-enoyl]oxypropan-2-yl] octadec-17-enoate

C35H65O8P (644.4417)


   

[(2R)-1-phosphonooxy-3-[(E)-tetradec-9-enoyl]oxypropan-2-yl] (E)-octadec-9-enoate

[(2R)-1-phosphonooxy-3-[(E)-tetradec-9-enoyl]oxypropan-2-yl] (E)-octadec-9-enoate

C35H65O8P (644.4417)


   

[(2R)-3-phosphonooxy-2-[(E)-tetradec-9-enoyl]oxypropyl] (E)-octadec-4-enoate

[(2R)-3-phosphonooxy-2-[(E)-tetradec-9-enoyl]oxypropyl] (E)-octadec-4-enoate

C35H65O8P (644.4417)


   

[(2R)-3-phosphonooxy-2-tetradecanoyloxypropyl] (2E,4E)-octadeca-2,4-dienoate

[(2R)-3-phosphonooxy-2-tetradecanoyloxypropyl] (2E,4E)-octadeca-2,4-dienoate

C35H65O8P (644.4417)


   

[(2R)-1-phosphonooxy-3-[(E)-tetradec-9-enoyl]oxypropan-2-yl] (E)-octadec-11-enoate

[(2R)-1-phosphonooxy-3-[(E)-tetradec-9-enoyl]oxypropan-2-yl] (E)-octadec-11-enoate

C35H65O8P (644.4417)


   

[(2R)-3-phosphonooxy-2-[(E)-tetradec-9-enoyl]oxypropyl] (E)-octadec-9-enoate

[(2R)-3-phosphonooxy-2-[(E)-tetradec-9-enoyl]oxypropyl] (E)-octadec-9-enoate

C35H65O8P (644.4417)


   

2-[[3-decanoyloxy-2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[3-decanoyloxy-2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C34H63NO8P+ (644.4291)


   

[(2R)-1-phosphonooxy-3-tetradecanoyloxypropan-2-yl] (9E,12E)-octadeca-9,12-dienoate

[(2R)-1-phosphonooxy-3-tetradecanoyloxypropan-2-yl] (9E,12E)-octadeca-9,12-dienoate

C35H65O8P (644.4417)


   

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(E)-undec-4-enoyl]oxypropan-2-yl] (9E,11E,13E)-hexadeca-9,11,13-trienoate

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(E)-undec-4-enoyl]oxypropan-2-yl] (9E,11E,13E)-hexadeca-9,11,13-trienoate

C33H57O10P (644.3689)


   

[(2R)-3-phosphonooxy-2-[(E)-tetradec-9-enoyl]oxypropyl] (E)-octadec-6-enoate

[(2R)-3-phosphonooxy-2-[(E)-tetradec-9-enoyl]oxypropyl] (E)-octadec-6-enoate

C35H65O8P (644.4417)


   

[2-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-3-phosphonooxypropyl] hexadecanoate

[2-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-3-phosphonooxypropyl] hexadecanoate

C35H65O8P (644.4417)


   

[(2R)-3-phosphonooxy-2-tetradecanoyloxypropyl] (6E,9E)-octadeca-6,9-dienoate

[(2R)-3-phosphonooxy-2-tetradecanoyloxypropyl] (6E,9E)-octadeca-6,9-dienoate

C35H65O8P (644.4417)


   

[(2R)-1-[(E)-hexadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (E)-hexadec-7-enoate

[(2R)-1-[(E)-hexadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (E)-hexadec-7-enoate

C35H65O8P (644.4417)


   

[(2R)-1-phosphonooxy-3-[(E)-tetradec-9-enoyl]oxypropan-2-yl] (E)-octadec-4-enoate

[(2R)-1-phosphonooxy-3-[(E)-tetradec-9-enoyl]oxypropan-2-yl] (E)-octadec-4-enoate

C35H65O8P (644.4417)


   

[(2R)-1-decanoyloxy-3-phosphonooxypropan-2-yl] (13E,16E)-docosa-13,16-dienoate

[(2R)-1-decanoyloxy-3-phosphonooxypropan-2-yl] (13E,16E)-docosa-13,16-dienoate

C35H65O8P (644.4417)


   

[(2R)-1-phosphonooxy-3-tetradecanoyloxypropan-2-yl] (2E,4E)-octadeca-2,4-dienoate

[(2R)-1-phosphonooxy-3-tetradecanoyloxypropan-2-yl] (2E,4E)-octadeca-2,4-dienoate

C35H65O8P (644.4417)


   

[(2R)-3-phosphonooxy-2-[(E)-tetradec-9-enoyl]oxypropyl] octadec-17-enoate

[(2R)-3-phosphonooxy-2-[(E)-tetradec-9-enoyl]oxypropyl] octadec-17-enoate

C35H65O8P (644.4417)


   

[(2R)-2-[(E)-pentadec-9-enoyl]oxy-3-phosphonooxypropyl] (E)-heptadec-9-enoate

[(2R)-2-[(E)-pentadec-9-enoyl]oxy-3-phosphonooxypropyl] (E)-heptadec-9-enoate

C35H65O8P (644.4417)


   

[(2R)-1-phosphonooxy-3-tetradecanoyloxypropan-2-yl] (9E,11E)-octadeca-9,11-dienoate

[(2R)-1-phosphonooxy-3-tetradecanoyloxypropan-2-yl] (9E,11E)-octadeca-9,11-dienoate

C35H65O8P (644.4417)


   

[(2R)-1-phosphonooxy-3-tetradecanoyloxypropan-2-yl] (6E,9E)-octadeca-6,9-dienoate

[(2R)-1-phosphonooxy-3-tetradecanoyloxypropan-2-yl] (6E,9E)-octadeca-6,9-dienoate

C35H65O8P (644.4417)


   

[(2R)-1-pentadecanoyloxy-3-phosphonooxypropan-2-yl] (9E,12E)-heptadeca-9,12-dienoate

[(2R)-1-pentadecanoyloxy-3-phosphonooxypropan-2-yl] (9E,12E)-heptadeca-9,12-dienoate

C35H65O8P (644.4417)


   

[(2R)-1-dodecanoyloxy-3-phosphonooxypropan-2-yl] (11E,14E)-icosa-11,14-dienoate

[(2R)-1-dodecanoyloxy-3-phosphonooxypropan-2-yl] (11E,14E)-icosa-11,14-dienoate

C35H65O8P (644.4417)


   

[(2R)-2-dodecanoyloxy-3-phosphonooxypropyl] (11E,14E)-icosa-11,14-dienoate

[(2R)-2-dodecanoyloxy-3-phosphonooxypropyl] (11E,14E)-icosa-11,14-dienoate

C35H65O8P (644.4417)


   

[(2R)-3-phosphonooxy-2-tetradecanoyloxypropyl] (9E,11E)-octadeca-9,11-dienoate

[(2R)-3-phosphonooxy-2-tetradecanoyloxypropyl] (9E,11E)-octadeca-9,11-dienoate

C35H65O8P (644.4417)


   

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-undecanoyloxypropan-2-yl] (7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoate

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-undecanoyloxypropan-2-yl] (7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoate

C33H57O10P (644.3689)


   

[(2R)-1-phosphonooxy-3-[(E)-tetradec-9-enoyl]oxypropan-2-yl] (E)-octadec-13-enoate

[(2R)-1-phosphonooxy-3-[(E)-tetradec-9-enoyl]oxypropan-2-yl] (E)-octadec-13-enoate

C35H65O8P (644.4417)


   

2-[[3-butanoyloxy-2-[(10Z,13Z,16Z)-docosa-10,13,16-trienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[3-butanoyloxy-2-[(10Z,13Z,16Z)-docosa-10,13,16-trienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C34H63NO8P+ (644.4291)


   

2-[[3-decanoyloxy-2-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[3-decanoyloxy-2-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C34H63NO8P+ (644.4291)


   

2-[[3-hexanoyloxy-2-[(11Z,14Z,17Z)-icosa-11,14,17-trienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[3-hexanoyloxy-2-[(11Z,14Z,17Z)-icosa-11,14,17-trienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C34H63NO8P+ (644.4291)


   

2-[hydroxy-[2-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]oxy-3-octanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium

2-[hydroxy-[2-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]oxy-3-octanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C34H63NO8P+ (644.4291)


   

1-(9Z,12Z-octadecadienoyl)-2-tetradecanoyl-glycero-3-phosphate

1-(9Z,12Z-octadecadienoyl)-2-tetradecanoyl-glycero-3-phosphate

C35H65O8P (644.4417)


   

1,2-di-(9Z-hexadecenoyl)-sn-glycero-3-phosphate

1,2-di-(9Z-hexadecenoyl)-sn-glycero-3-phosphate

C35H65O8P (644.4417)


   

1-Oleoyl-2-myristoyl-sn-glycero-3-phosphate(2-)

1-Oleoyl-2-myristoyl-sn-glycero-3-phosphate(2-)

C35H65O8P (644.4417)


A 1,2-diacyl-sn-glycerol 3-phosphate(2-) obtained by deprotonation of the phosphate OH groups of 1-oleoyl-2-myristoyl-sn-glycero-3-phosphate.

   

1-Myristoyl-2-oleoyl-sn-glycero-3-phosphate(2-)

1-Myristoyl-2-oleoyl-sn-glycero-3-phosphate(2-)

C35H65O8P (644.4417)


A 1,2-diacyl-sn-glycerol 3-phosphate(2-) obtained by deprotonation of the phosphate OH groups of 1-myristoyl-2-oleoyl-sn-glycero-3-phosphate.

   

1-hexadecanoyl-2-[(9Z)-hexadec-9-enoyl]-sn-glycero-3-phosphate(2-)

1-hexadecanoyl-2-[(9Z)-hexadec-9-enoyl]-sn-glycero-3-phosphate(2-)

C35H65O8P (644.4417)


A 1,2-diacyl-sn-glycerol 3-phosphate(2-) ion in which the acyl groups at C-1 and C-2 are hexadecanoyl and (9Z)-hexadec-9-enoyl respectively.

   

1,2-di-[(9Z)-hexadecenoyl]-sn-glycero-3-phosphate

1,2-di-[(9Z)-hexadecenoyl]-sn-glycero-3-phosphate

C35H65O8P (644.4417)


A 1,2-diacyl-sn-glycerol 3-phosphate in which the acyl substituents at positions 1 and 2 are both (9Z)-hexadecenoyl (palmitoleoyl).

   

MGDG O-28:8

MGDG O-28:8

C37H56O9 (644.3924)


   
   
   
   

PA O-18:0/13:4;O2

PA O-18:0/13:4;O2

C34H61O9P (644.4053)


   

PA O-20:0/12:3;O

PA O-20:0/12:3;O

C35H65O8P (644.4417)


   
   
   
   

PA P-18:0/13:3;O2

PA P-18:0/13:3;O2

C34H61O9P (644.4053)


   

PA P-18:1/12:3;O3

PA P-18:1/12:3;O3

C33H57O10P (644.3689)


   

PA 18:0/13:3;O

PA 18:0/13:3;O

C34H61O9P (644.4053)


   

PA 18:1/12:3;O2

PA 18:1/12:3;O2

C33H57O10P (644.3689)


   

PA 18:2/12:2;O2

PA 18:2/12:2;O2

C33H57O10P (644.3689)


   

PA 20:1/11:2;O

PA 20:1/11:2;O

C34H61O9P (644.4053)


   
   
   

PA 22:2/9:1;O

PA 22:2/9:1;O

C34H61O9P (644.4053)


   
   
   
   
   
   
   
   
   

PG O-10:0/18:4

PG O-10:0/18:4

C34H61O9P (644.4053)


   
   

PG P-20:1/7:3;O

PG P-20:1/7:3;O

C33H57O10P (644.3689)


   
   
   
   
   
   
   

ST 27:0;O6;GlcA

ST 27:0;O6;GlcA

C33H56O12 (644.3772)


   

ST 27:1;O7;Hex

ST 27:1;O7;Hex

C33H56O12 (644.3772)


   

ST 28:0;O6;Hex

ST 28:0;O6;Hex

C34H60O11 (644.4135)


   

2-{2-hydroxy-7-[(3-hydroxy-5-methoxy-3-methyl-5-oxopentanoyl)oxy]-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl}-6-methyl-5-methylideneheptanoic acid

2-{2-hydroxy-7-[(3-hydroxy-5-methoxy-3-methyl-5-oxopentanoyl)oxy]-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl}-6-methyl-5-methylideneheptanoic acid

C38H60O8 (644.4288)


   

(3s)-5-{[(1r,3as,5r,5ar,7s,9as,11s,11ar)-1-[(2r)-1-[(2s)-3,4-dimethyl-5-oxo-2h-furan-2-yl]propan-2-yl]-5,11-dihydroxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-3-hydroxy-3-methyl-5-oxopentanoic acid

(3s)-5-{[(1r,3as,5r,5ar,7s,9as,11s,11ar)-1-[(2r)-1-[(2s)-3,4-dimethyl-5-oxo-2h-furan-2-yl]propan-2-yl]-5,11-dihydroxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-3-hydroxy-3-methyl-5-oxopentanoic acid

C37H56O9 (644.3924)


   

(1r,3r,4r,5r,6s,10s,12s,13s,16r,18s,21r)-4,6,12,17,17-pentamethyl-8-(2-methylpropanoyl)-18-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}-9-oxahexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docos-7-en-3-yl acetate

(1r,3r,4r,5r,6s,10s,12s,13s,16r,18s,21r)-4,6,12,17,17-pentamethyl-8-(2-methylpropanoyl)-18-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}-9-oxahexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docos-7-en-3-yl acetate

C37H56O9 (644.3924)


   

(2s,6r)-6-[(1r,3as,5ar,7r,9as,11s,11ar)-11-hydroxy-7-{[(3r)-3-hydroxy-5-methoxy-3-methyl-5-oxopentanoyl]oxy}-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-2-methyl-3-methylideneheptanoic acid

(2s,6r)-6-[(1r,3as,5ar,7r,9as,11s,11ar)-11-hydroxy-7-{[(3r)-3-hydroxy-5-methoxy-3-methyl-5-oxopentanoyl]oxy}-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-2-methyl-3-methylideneheptanoic acid

C38H60O8 (644.4288)


   

(1r,2r,6s,10s,11r,12s,13s,14r,15r)-13-(acetyloxy)-1-hydroxy-8,12-bis(hydroxymethyl)-4,12,15-trimethyl-5-oxotetracyclo[8.5.0.0²,⁶.0¹¹,¹³]pentadeca-3,8-dien-14-yl hexadecanoate

(1r,2r,6s,10s,11r,12s,13s,14r,15r)-13-(acetyloxy)-1-hydroxy-8,12-bis(hydroxymethyl)-4,12,15-trimethyl-5-oxotetracyclo[8.5.0.0²,⁶.0¹¹,¹³]pentadeca-3,8-dien-14-yl hexadecanoate

C38H60O8 (644.4288)


   

(2s,6r)-6-[(1r,3as,5ar,7r,9as,11s,11ar)-11-hydroxy-7-[(3-hydroxy-5-methoxy-3-methyl-5-oxopentanoyl)oxy]-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-2-methyl-3-methylideneheptanoic acid

(2s,6r)-6-[(1r,3as,5ar,7r,9as,11s,11ar)-11-hydroxy-7-[(3-hydroxy-5-methoxy-3-methyl-5-oxopentanoyl)oxy]-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-2-methyl-3-methylideneheptanoic acid

C38H60O8 (644.4288)


   

(2s,3r)-2-{[(2-amino-3-hydroxy-4-methylphenyl)(hydroxy)methylidene]amino}-3-hydroxy-n-[(2r)-3-methyl-1-[(5s)-2-methyl-5-[methyl({methyl[(2s)-3-methyl-1-oxobutan-2-yl]carbamoyl}methyl)carbamoyl]pyrrolidin-1-yl]-1-oxobut-3-en-2-yl]butanimidic acid

(2s,3r)-2-{[(2-amino-3-hydroxy-4-methylphenyl)(hydroxy)methylidene]amino}-3-hydroxy-n-[(2r)-3-methyl-1-[(5s)-2-methyl-5-[methyl({methyl[(2s)-3-methyl-1-oxobutan-2-yl]carbamoyl}methyl)carbamoyl]pyrrolidin-1-yl]-1-oxobut-3-en-2-yl]butanimidic acid

C32H48N6O8 (644.3533)


   

(2r)-2-[(1r,3s,3ar,5ar,7r,9as,11ar)-3-hydroxy-7-{[(3s)-3-hydroxy-5-methoxy-3-methyl-5-oxopentanoyl]oxy}-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-6-methyl-5-methylideneheptanoic acid

(2r)-2-[(1r,3s,3ar,5ar,7r,9as,11ar)-3-hydroxy-7-{[(3s)-3-hydroxy-5-methoxy-3-methyl-5-oxopentanoyl]oxy}-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-6-methyl-5-methylideneheptanoic acid

C38H60O8 (644.4288)


   

20-O-(2,3-dimethylbutanoyl)-13-O-dodecanoylingenol

20-O-(2,3-Dimethylbutanoyl)-13-O-dodecanoyl ingenol

C38H60O8 (644.4288)


{"Ingredient_id": "HBIN003425","Ingredient_name": "20-O-(2,3-dimethylbutanoyl)-13-O-dodecanoylingenol","Alias": "20-O-(2,3-Dimethylbutanoyl)-13-O-dodecanoyl ingenol","Ingredient_formula": "C38H60O8","Ingredient_Smile": "NA","Ingredient_weight": "644.98","OB_score": "24.1740825","CAS_id": "NA","SymMap_id": "SMIT01210","TCMID_id": "NA","TCMSP_id": "MOL002582","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

   

20-o-(2,3-dimethylbutanoyl)-13-o-dodecanoyl-ingenol

NA

C38H60O8 (644.4288)


{"Ingredient_id": "HBIN003426","Ingredient_name": "20-o-(2,3-dimethylbutanoyl)-13-o-dodecanoyl-ingenol","Alias": "NA","Ingredient_formula": "C38H60O8","Ingredient_Smile": "CCCCCCCCCCCC(=O)OC12CC(C34C=C(C(C3(C(C(=CC(C1C2(C)C)C4=O)COC(=O)C(C)C(C)C)O)O)O)C)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "6325","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

   

3-o-(2,3-dimethylbutanoyl)-13-o-dodecanoyl-ingenol

NA

C38H60O8 (644.4288)


{"Ingredient_id": "HBIN008994","Ingredient_name": "3-o-(2,3-dimethylbutanoyl)-13-o-dodecanoyl-ingenol","Alias": "NA","Ingredient_formula": "C38H60O8","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "SMIT15160","TCMID_id": "6324","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

   

6'-o-α-l-rhamnopyranosyl-4-epimicrolepin

NA

C33H56O12 (644.3772)


{"Ingredient_id": "HBIN012632","Ingredient_name": "6'-o-\u03b1-l-rhamnopyranosyl-4-epimicrolepin","Alias": "NA","Ingredient_formula": "C33H56O12","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "18683","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

   

(2s)-6-[(1r,3as,7r,9as,11s,11ar)-11-hydroxy-7-[(3-hydroxy-5-methoxy-3-methyl-5-oxopentanoyl)oxy]-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-2-methyl-3-methylideneheptanoic acid

(2s)-6-[(1r,3as,7r,9as,11s,11ar)-11-hydroxy-7-[(3-hydroxy-5-methoxy-3-methyl-5-oxopentanoyl)oxy]-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-2-methyl-3-methylideneheptanoic acid

C38H60O8 (644.4288)


   

3-[3,10-bis(acetyloxy)-2,7,7,11,16-pentamethyl-5-oxo-6-oxatetracyclo[9.7.0.0²,⁸.0¹²,¹⁶]octadec-12-en-15-yl]-5-(3,3-dimethyloxiran-2-yl)oxolan-2-yl acetate

3-[3,10-bis(acetyloxy)-2,7,7,11,16-pentamethyl-5-oxo-6-oxatetracyclo[9.7.0.0²,⁸.0¹²,¹⁶]octadec-12-en-15-yl]-5-(3,3-dimethyloxiran-2-yl)oxolan-2-yl acetate

C36H52O10 (644.356)


   

5-(acetyloxy)-6-[3,7-bis(acetyloxy)-4-methoxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-2-methylhept-2-enoic acid

5-(acetyloxy)-6-[3,7-bis(acetyloxy)-4-methoxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-2-methylhept-2-enoic acid

C37H56O9 (644.3924)


   

methyl (1s,14r,15z,18s)-15-ethylidene-12-[(1s,14r,15z)-15-ethylidene-13-(hydroxymethyl)-3-methyl-3,17-diazapentacyclo[12.3.1.0²,¹⁰.0⁴,⁹.0¹²,¹⁷]octadeca-2(10),4,6,8-tetraen-7-yl]-17-methyl-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraene-18-carboxylate

methyl (1s,14r,15z,18s)-15-ethylidene-12-[(1s,14r,15z)-15-ethylidene-13-(hydroxymethyl)-3-methyl-3,17-diazapentacyclo[12.3.1.0²,¹⁰.0⁴,⁹.0¹²,¹⁷]octadeca-2(10),4,6,8-tetraen-7-yl]-17-methyl-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraene-18-carboxylate

C41H48N4O3 (644.3726)


   

(2s,6r)-6-[(1r,3as,5ar,7r,9as,11s,11ar)-11-hydroxy-7-{[(3s)-3-hydroxy-5-methoxy-3-methyl-5-oxopentanoyl]oxy}-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-2-methyl-3-methylideneheptanoic acid

(2s,6r)-6-[(1r,3as,5ar,7r,9as,11s,11ar)-11-hydroxy-7-{[(3s)-3-hydroxy-5-methoxy-3-methyl-5-oxopentanoyl]oxy}-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-2-methyl-3-methylideneheptanoic acid

C38H60O8 (644.4288)


   

[(1r,2r,5s,13s,16e,17r,18r,19s,25s,26r,28r)-16-ethylidene-5,11,30,39-tetramethyl-4,6-dioxa-11,14,30,39-tetraazaundecacyclo[26.10.1.1¹³,¹⁷.0²,²⁶.0⁵,²⁵.0⁷,²³.0¹⁰,²².0¹²,²¹.0¹⁴,¹⁹.0²⁹,³⁷.0³¹,³⁶]tetraconta-7,9,12(21),22,29(37),31,33,35-octaen-18-yl]methanol

[(1r,2r,5s,13s,16e,17r,18r,19s,25s,26r,28r)-16-ethylidene-5,11,30,39-tetramethyl-4,6-dioxa-11,14,30,39-tetraazaundecacyclo[26.10.1.1¹³,¹⁷.0²,²⁶.0⁵,²⁵.0⁷,²³.0¹⁰,²².0¹²,²¹.0¹⁴,¹⁹.0²⁹,³⁷.0³¹,³⁶]tetraconta-7,9,12(21),22,29(37),31,33,35-octaen-18-yl]methanol

C41H48N4O3 (644.3726)


   

3-{7-[(3-butoxy-3-oxopropanoyl)oxy]-15-hydroxy-1,6,6,10,17,21-hexamethyl-14-oxapentacyclo[11.7.1.0²,¹¹.0⁵,¹⁰.0¹⁸,²¹]henicos-2(11)-en-15-yl}-2-methylbutanoic acid

3-{7-[(3-butoxy-3-oxopropanoyl)oxy]-15-hydroxy-1,6,6,10,17,21-hexamethyl-14-oxapentacyclo[11.7.1.0²,¹¹.0⁵,¹⁰.0¹⁸,²¹]henicos-2(11)-en-15-yl}-2-methylbutanoic acid

C38H60O8 (644.4288)


   

methyl (1s,4ar,6as,6br,8ar,10s,12ar,12br,14bs)-10-(acetyloxy)-9,9-bis[(acetyloxy)methyl]-1-hydroxy-2,2,6a,6b,12a-pentamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

methyl (1s,4ar,6as,6br,8ar,10s,12ar,12br,14bs)-10-(acetyloxy)-9,9-bis[(acetyloxy)methyl]-1-hydroxy-2,2,6a,6b,12a-pentamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

C37H56O9 (644.3924)


   

(2e,5s,6s)-6-[(1r,3s,3ar,4r,5ar,7r,9as,11ar)-3,7-bis(acetyloxy)-4-methoxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-(acetyloxy)-2-methylhept-2-enoic acid

(2e,5s,6s)-6-[(1r,3s,3ar,4r,5ar,7r,9as,11ar)-3,7-bis(acetyloxy)-4-methoxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-(acetyloxy)-2-methylhept-2-enoic acid

C37H56O9 (644.3924)


   

{16-ethylidene-5,11,30,39-tetramethyl-4,6-dioxa-11,14,30,39-tetraazaundecacyclo[26.10.1.1¹³,¹⁷.0²,²⁶.0⁵,²⁵.0⁷,²³.0¹⁰,²².0¹²,²¹.0¹⁴,¹⁹.0²⁹,³⁷.0³¹,³⁶]tetraconta-7,9,12(21),22,29(37),31,33,35-octaen-18-yl}methanol

{16-ethylidene-5,11,30,39-tetramethyl-4,6-dioxa-11,14,30,39-tetraazaundecacyclo[26.10.1.1¹³,¹⁷.0²,²⁶.0⁵,²⁵.0⁷,²³.0¹⁰,²².0¹²,²¹.0¹⁴,¹⁹.0²⁹,³⁷.0³¹,³⁶]tetraconta-7,9,12(21),22,29(37),31,33,35-octaen-18-yl}methanol

C41H48N4O3 (644.3726)


   

8-hydroxy-2,8,10,13,18,18-hexamethyl-6-(2-methylprop-1-en-1-yl)-16-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-oxapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁴,¹⁹]henicosa-15,19-diene-12,17-dione

8-hydroxy-2,8,10,13,18,18-hexamethyl-6-(2-methylprop-1-en-1-yl)-16-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-oxapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁴,¹⁹]henicosa-15,19-diene-12,17-dione

C36H52O10 (644.356)


   

7-[(hexanoyloxy)methyl]-4,5,6-trihydroxy-3,11,11,14-tetramethyl-15-oxotetracyclo[7.5.1.0¹,⁵.0¹⁰,¹²]pentadeca-2,7-dien-12-yl dodecanoate

7-[(hexanoyloxy)methyl]-4,5,6-trihydroxy-3,11,11,14-tetramethyl-15-oxotetracyclo[7.5.1.0¹,⁵.0¹⁰,¹²]pentadeca-2,7-dien-12-yl dodecanoate

C38H60O8 (644.4288)


   

(2e,6s)-6-[(1r,3s,3ar,4s,5ar,7r,9as,11ar)-3,7-bis(acetyloxy)-4-methoxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-(acetyloxy)-2-methylhept-2-enoic acid

(2e,6s)-6-[(1r,3s,3ar,4s,5ar,7r,9as,11ar)-3,7-bis(acetyloxy)-4-methoxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-(acetyloxy)-2-methylhept-2-enoic acid

C37H56O9 (644.3924)


   

2,4,5-trihydroxyoxan-3-yl 2-[7-(acetyloxy)-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-6-methyl-5-methylideneheptanoate

2,4,5-trihydroxyoxan-3-yl 2-[7-(acetyloxy)-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-6-methyl-5-methylideneheptanoate

C38H60O8 (644.4288)


   

13-(acetyloxy)-1,6-dihydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-5-oxotetracyclo[8.5.0.0²,⁶.0¹¹,¹³]pentadeca-3,8-dien-14-yl hexadecanoate

13-(acetyloxy)-1,6-dihydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-5-oxotetracyclo[8.5.0.0²,⁶.0¹¹,¹³]pentadeca-3,8-dien-14-yl hexadecanoate

C38H60O8 (644.4288)


   

methyl (1r,12s,14s,15e,18s)-15-ethylidene-12-[(1s,12s,13s,14r,15e)-15-ethylidene-13-(hydroxymethyl)-3-methyl-3,17-diazapentacyclo[12.3.1.0²,¹⁰.0⁴,⁹.0¹²,¹⁷]octadeca-2(10),4,6,8-tetraen-7-yl]-17-methyl-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraene-18-carboxylate

methyl (1r,12s,14s,15e,18s)-15-ethylidene-12-[(1s,12s,13s,14r,15e)-15-ethylidene-13-(hydroxymethyl)-3-methyl-3,17-diazapentacyclo[12.3.1.0²,¹⁰.0⁴,⁹.0¹²,¹⁷]octadeca-2(10),4,6,8-tetraen-7-yl]-17-methyl-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraene-18-carboxylate

C41H48N4O3 (644.3726)


   

(1r,2s,4s,6r,8r,9s,10s,13s,14s)-8-hydroxy-2,8,10,13,18,18-hexamethyl-6-(2-methylprop-1-en-1-yl)-16-{[(2r,3r,4s,5r,6s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-oxapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁴,¹⁹]henicosa-15,19-diene-12,17-dione

(1r,2s,4s,6r,8r,9s,10s,13s,14s)-8-hydroxy-2,8,10,13,18,18-hexamethyl-6-(2-methylprop-1-en-1-yl)-16-{[(2r,3r,4s,5r,6s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-oxapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁴,¹⁹]henicosa-15,19-diene-12,17-dione

C36H52O10 (644.356)


   

(1s,2s,4r,6s,8s,9r,10r,13r,14r)-8-hydroxy-2,8,10,13,18,18-hexamethyl-6-(2-methylprop-1-en-1-yl)-16-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-oxapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁴,¹⁹]henicosa-15,19-diene-12,17-dione

(1s,2s,4r,6s,8s,9r,10r,13r,14r)-8-hydroxy-2,8,10,13,18,18-hexamethyl-6-(2-methylprop-1-en-1-yl)-16-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-oxapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁴,¹⁹]henicosa-15,19-diene-12,17-dione

C36H52O10 (644.356)


   

6-{11-hydroxy-7-[(3-hydroxy-5-methoxy-3-methyl-5-oxopentanoyl)oxy]-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl}-2-methyl-3-methylideneheptanoic acid

6-{11-hydroxy-7-[(3-hydroxy-5-methoxy-3-methyl-5-oxopentanoyl)oxy]-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl}-2-methyl-3-methylideneheptanoic acid

C38H60O8 (644.4288)


   

(2e,5s,6s)-6-[(1r,3s,3ar,4r,5ar,7s,9as,11ar)-3,7-bis(acetyloxy)-4-methoxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-(acetyloxy)-2-methylhept-2-enoic acid

(2e,5s,6s)-6-[(1r,3s,3ar,4r,5ar,7s,9as,11ar)-3,7-bis(acetyloxy)-4-methoxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-(acetyloxy)-2-methylhept-2-enoic acid

C37H56O9 (644.3924)


   

12-[(hexanoyloxy)methyl]-4,9-dimethyl-15-(propan-2-ylidene)-11-(pyridine-3-carbonyloxy)-5-oxatricyclo[10.3.0.0⁴,⁶]pentadec-9-en-2-yl pyridine-3-carboxylate

12-[(hexanoyloxy)methyl]-4,9-dimethyl-15-(propan-2-ylidene)-11-(pyridine-3-carbonyloxy)-5-oxatricyclo[10.3.0.0⁴,⁶]pentadec-9-en-2-yl pyridine-3-carboxylate

C38H48N2O7 (644.3461)


   

4,6,12,17,17-pentamethyl-8-(2-methylpropanoyl)-18-[(3,4,5-trihydroxyoxan-2-yl)oxy]-9-oxahexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docos-7-en-3-yl acetate

4,6,12,17,17-pentamethyl-8-(2-methylpropanoyl)-18-[(3,4,5-trihydroxyoxan-2-yl)oxy]-9-oxahexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docos-7-en-3-yl acetate

C37H56O9 (644.3924)


   

(2e,5s,6s)-6-[(1r,3s,3ar,4r,5as,7r,9as,11ar)-3,7-bis(acetyloxy)-4-methoxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-(acetyloxy)-2-methylhept-2-enoic acid

(2e,5s,6s)-6-[(1r,3s,3ar,4r,5as,7r,9as,11ar)-3,7-bis(acetyloxy)-4-methoxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-(acetyloxy)-2-methylhept-2-enoic acid

C37H56O9 (644.3924)


   

(1s,2s,4r,6r,8s,9r,10r,13r,14r)-8-hydroxy-2,8,10,13,18,18-hexamethyl-6-(2-methylprop-1-en-1-yl)-16-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-oxapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁴,¹⁹]henicosa-15,19-diene-12,17-dione

(1s,2s,4r,6r,8s,9r,10r,13r,14r)-8-hydroxy-2,8,10,13,18,18-hexamethyl-6-(2-methylprop-1-en-1-yl)-16-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-oxapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁴,¹⁹]henicosa-15,19-diene-12,17-dione

C36H52O10 (644.356)


   

methyl (1r,2r,4as,6as,6br,10s,12ar)-10-(acetyloxy)-9,9-bis[(acetyloxy)methyl]-1-hydroxy-1,2,6a,6b,12a-pentamethyl-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

methyl (1r,2r,4as,6as,6br,10s,12ar)-10-(acetyloxy)-9,9-bis[(acetyloxy)methyl]-1-hydroxy-1,2,6a,6b,12a-pentamethyl-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

C37H56O9 (644.3924)


   

(1s,2r,4s,6r,9e,11s,12s)-12-[(hexanoyloxy)methyl]-4,9-dimethyl-15-(propan-2-ylidene)-11-(pyridine-3-carbonyloxy)-5-oxatricyclo[10.3.0.0⁴,⁶]pentadec-9-en-2-yl pyridine-3-carboxylate

(1s,2r,4s,6r,9e,11s,12s)-12-[(hexanoyloxy)methyl]-4,9-dimethyl-15-(propan-2-ylidene)-11-(pyridine-3-carbonyloxy)-5-oxatricyclo[10.3.0.0⁴,⁶]pentadec-9-en-2-yl pyridine-3-carboxylate

C38H48N2O7 (644.3461)


   

3,4,5-trihydroxyoxan-2-yl 2-[7-(acetyloxy)-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-6-methyl-5-methylideneheptanoate

3,4,5-trihydroxyoxan-2-yl 2-[7-(acetyloxy)-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-6-methyl-5-methylideneheptanoate

C38H60O8 (644.4288)


   

(1's,2r,4s,4'r,5s,6s,7'r,8'r,9's,10'e,12'e,14'r,16'e,19'r)-4,8',9'-trihydroxy-10'-(hydroxymethyl)-7'-methoxy-5,6',14',16'-tetramethyl-6-[(2e)-4-methylpent-2-en-2-yl]-2',20'-dioxaspiro[oxane-2,21'-tricyclo[17.3.1.0⁴,⁹]tricosane]-5',10',12',16'-tetraen-3'-one

(1's,2r,4s,4'r,5s,6s,7'r,8'r,9's,10'e,12'e,14'r,16'e,19'r)-4,8',9'-trihydroxy-10'-(hydroxymethyl)-7'-methoxy-5,6',14',16'-tetramethyl-6-[(2e)-4-methylpent-2-en-2-yl]-2',20'-dioxaspiro[oxane-2,21'-tricyclo[17.3.1.0⁴,⁹]tricosane]-5',10',12',16'-tetraen-3'-one

C37H56O9 (644.3924)


   

methyl (10r,28r,29r)-10,28-diethyl-2-oxa-6,14,24,37-tetraazaundecacyclo[26.9.2.1¹⁰,¹⁴.0¹,³⁰.0³,²⁰.0⁵,¹⁸.0⁷,¹⁷.0²²,³⁰.0²⁴,²⁹.0³¹,³⁶.0¹⁷,⁴⁰]tetraconta-3(20),4,7,11,18,31,33,35-octaene-38-carboxylate

methyl (10r,28r,29r)-10,28-diethyl-2-oxa-6,14,24,37-tetraazaundecacyclo[26.9.2.1¹⁰,¹⁴.0¹,³⁰.0³,²⁰.0⁵,¹⁸.0⁷,¹⁷.0²²,³⁰.0²⁴,²⁹.0³¹,³⁶.0¹⁷,⁴⁰]tetraconta-3(20),4,7,11,18,31,33,35-octaene-38-carboxylate

C41H48N4O3 (644.3726)


   

methyl 10-(acetyloxy)-9,9-bis[(acetyloxy)methyl]-1-hydroxy-2,2,6a,6b,12a-pentamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

methyl 10-(acetyloxy)-9,9-bis[(acetyloxy)methyl]-1-hydroxy-2,2,6a,6b,12a-pentamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

C37H56O9 (644.3924)


   

(2r,3r,4s,5r)-2,4,5-trihydroxyoxan-3-yl (2r)-2-[(1r,3ar,5ar,7r,9as,11ar)-7-(acetyloxy)-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-6-methyl-5-methylideneheptanoate

(2r,3r,4s,5r)-2,4,5-trihydroxyoxan-3-yl (2r)-2-[(1r,3ar,5ar,7r,9as,11ar)-7-(acetyloxy)-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-6-methyl-5-methylideneheptanoate

C38H60O8 (644.4288)


   

(3r)-3-[(1s,7r,13r,17r,18r)-7-[(3-butoxy-3-oxopropanoyl)oxy]-15-hydroxy-1,6,6,10,17,21-hexamethyl-14-oxapentacyclo[11.7.1.0²,¹¹.0⁵,¹⁰.0¹⁸,²¹]henicos-2(11)-en-15-yl]-2-methylbutanoic acid

(3r)-3-[(1s,7r,13r,17r,18r)-7-[(3-butoxy-3-oxopropanoyl)oxy]-15-hydroxy-1,6,6,10,17,21-hexamethyl-14-oxapentacyclo[11.7.1.0²,¹¹.0⁵,¹⁰.0¹⁸,²¹]henicos-2(11)-en-15-yl]-2-methylbutanoic acid

C38H60O8 (644.4288)


   

(1s,4s,5r,6r,9s,10r,12s,14r)-7-[(hexanoyloxy)methyl]-4,5,6-trihydroxy-3,11,11,14-tetramethyl-15-oxotetracyclo[7.5.1.0¹,⁵.0¹⁰,¹²]pentadeca-2,7-dien-12-yl dodecanoate

(1s,4s,5r,6r,9s,10r,12s,14r)-7-[(hexanoyloxy)methyl]-4,5,6-trihydroxy-3,11,11,14-tetramethyl-15-oxotetracyclo[7.5.1.0¹,⁵.0¹⁰,¹²]pentadeca-2,7-dien-12-yl dodecanoate

C38H60O8 (644.4288)


   

(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl (2r)-2-[(1r,3ar,5ar,7r,9as,11ar)-7-(acetyloxy)-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-6-methyl-5-methylideneheptanoate

(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl (2r)-2-[(1r,3ar,5ar,7r,9as,11ar)-7-(acetyloxy)-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-6-methyl-5-methylideneheptanoate

C38H60O8 (644.4288)


   

methyl 10-(acetyloxy)-9,9-bis[(acetyloxy)methyl]-1-hydroxy-1,2,6a,6b,12a-pentamethyl-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

methyl 10-(acetyloxy)-9,9-bis[(acetyloxy)methyl]-1-hydroxy-1,2,6a,6b,12a-pentamethyl-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

C37H56O9 (644.3924)


   

(2s,3r,4s,5r)-4,5-dihydroxy-2-{[(1s,2r,3s,4r,7r,9s,12r,14s,17r,18r,19r,21r,22r)-2-hydroxy-3,8,8,17,19-pentamethyl-22-(prop-1-en-2-yl)-23,24-dioxaheptacyclo[19.2.1.0¹,¹⁸.0³,¹⁷.0⁴,¹⁴.0⁷,¹².0¹²,¹⁴]tetracosan-9-yl]oxy}oxan-3-yl acetate

(2s,3r,4s,5r)-4,5-dihydroxy-2-{[(1s,2r,3s,4r,7r,9s,12r,14s,17r,18r,19r,21r,22r)-2-hydroxy-3,8,8,17,19-pentamethyl-22-(prop-1-en-2-yl)-23,24-dioxaheptacyclo[19.2.1.0¹,¹⁸.0³,¹⁷.0⁴,¹⁴.0⁷,¹².0¹²,¹⁴]tetracosan-9-yl]oxy}oxan-3-yl acetate

C37H56O9 (644.3924)


   

5-({1-[1-(3,4-dimethyl-5-oxo-2h-furan-2-yl)propan-2-yl]-5,11-dihydroxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-7-yl}oxy)-3-hydroxy-3-methyl-5-oxopentanoic acid

5-({1-[1-(3,4-dimethyl-5-oxo-2h-furan-2-yl)propan-2-yl]-5,11-dihydroxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-7-yl}oxy)-3-hydroxy-3-methyl-5-oxopentanoic acid

C37H56O9 (644.3924)


   

(1s,2s,6r,10s,11r,13s,14r,15r)-13-(acetyloxy)-1,6-dihydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-5-oxotetracyclo[8.5.0.0²,⁶.0¹¹,¹³]pentadeca-3,8-dien-14-yl hexadecanoate

(1s,2s,6r,10s,11r,13s,14r,15r)-13-(acetyloxy)-1,6-dihydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-5-oxotetracyclo[8.5.0.0²,⁶.0¹¹,¹³]pentadeca-3,8-dien-14-yl hexadecanoate

C38H60O8 (644.4288)


   

(2r)-2-[(1r,2r,3ar,5ar,7r,9as,11ar)-2-hydroxy-7-{[(3s)-3-hydroxy-5-methoxy-3-methyl-5-oxopentanoyl]oxy}-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-6-methyl-5-methylideneheptanoic acid

(2r)-2-[(1r,2r,3ar,5ar,7r,9as,11ar)-2-hydroxy-7-{[(3s)-3-hydroxy-5-methoxy-3-methyl-5-oxopentanoyl]oxy}-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-6-methyl-5-methylideneheptanoic acid

C38H60O8 (644.4288)


   

(2s,3r,5s)-3-[(1s,2s,3r,8s,10s,11s,15r,16r)-3,10-bis(acetyloxy)-2,7,7,11,16-pentamethyl-5-oxo-6-oxatetracyclo[9.7.0.0²,⁸.0¹²,¹⁶]octadec-12-en-15-yl]-5-[(2r)-3,3-dimethyloxiran-2-yl]oxolan-2-yl acetate

(2s,3r,5s)-3-[(1s,2s,3r,8s,10s,11s,15r,16r)-3,10-bis(acetyloxy)-2,7,7,11,16-pentamethyl-5-oxo-6-oxatetracyclo[9.7.0.0²,⁸.0¹²,¹⁶]octadec-12-en-15-yl]-5-[(2r)-3,3-dimethyloxiran-2-yl]oxolan-2-yl acetate

C36H52O10 (644.356)


   

methyl (1r,2r,4as,6as,6br,8ar,10s,12ar,12br,14bs)-10-(acetyloxy)-9,9-bis[(acetyloxy)methyl]-1-hydroxy-1,2,6a,6b,12a-pentamethyl-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

methyl (1r,2r,4as,6as,6br,8ar,10s,12ar,12br,14bs)-10-(acetyloxy)-9,9-bis[(acetyloxy)methyl]-1-hydroxy-1,2,6a,6b,12a-pentamethyl-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

C37H56O9 (644.3924)


   

4,8',9'-trihydroxy-10'-(hydroxymethyl)-7'-methoxy-5,6',14',16'-tetramethyl-6-(4-methylpent-2-en-2-yl)-2',20'-dioxaspiro[oxane-2,21'-tricyclo[17.3.1.0⁴,⁹]tricosane]-5',10',12',16'-tetraen-3'-one

4,8',9'-trihydroxy-10'-(hydroxymethyl)-7'-methoxy-5,6',14',16'-tetramethyl-6-(4-methylpent-2-en-2-yl)-2',20'-dioxaspiro[oxane-2,21'-tricyclo[17.3.1.0⁴,⁹]tricosane]-5',10',12',16'-tetraen-3'-one

C37H56O9 (644.3924)


   

13-(acetyloxy)-1-hydroxy-8,12-bis(hydroxymethyl)-4,12,15-trimethyl-5-oxotetracyclo[8.5.0.0²,⁶.0¹¹,¹³]pentadeca-3,8-dien-14-yl hexadecanoate

13-(acetyloxy)-1-hydroxy-8,12-bis(hydroxymethyl)-4,12,15-trimethyl-5-oxotetracyclo[8.5.0.0²,⁶.0¹¹,¹³]pentadeca-3,8-dien-14-yl hexadecanoate

C38H60O8 (644.4288)


   

4,5-dihydroxy-2-{[2-hydroxy-3,8,8,17,19-pentamethyl-22-(prop-1-en-2-yl)-23,24-dioxaheptacyclo[19.2.1.0¹,¹⁸.0³,¹⁷.0⁴,¹⁴.0⁷,¹².0¹²,¹⁴]tetracosan-9-yl]oxy}oxan-3-yl acetate

4,5-dihydroxy-2-{[2-hydroxy-3,8,8,17,19-pentamethyl-22-(prop-1-en-2-yl)-23,24-dioxaheptacyclo[19.2.1.0¹,¹⁸.0³,¹⁷.0⁴,¹⁴.0⁷,¹².0¹²,¹⁴]tetracosan-9-yl]oxy}oxan-3-yl acetate

C37H56O9 (644.3924)